EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Assessing Patient Adherence to and Engagement With Digital Interventions for Depression in Clinical Trials: Systematic Literature Review

Ainslie Forbes iD, Madeline Rose Keleher iD, Michael Venditto iD, Faith DiBiasi iD

Journal of Medical Internet Research · 11.08.2023 · 25 · e43727

DOI: 10.2196/43727 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Medical Internet Research, online erschienen am 11.08.2023. Verfasst von Ainslie Forbes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, United States. Hauptthemen laut MEDLINE: Major Depressive Disorder, Mobile Applications. Die Arbeit wurde bisher 109-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

New approaches to the treatment of depression are necessary for patients who do not respond to current treatments or lack access to them because of barriers such as cost, stigma, and provider shortage. Digital interventions for depression are promising; however, low patient engagement could limit their effectiveness.

Objective

This systematic literature review (SLR) assessed how participant adherence to and engagement with digital interventions for depression have been measured in the published literature, what levels of adherence and engagement have been reported, and whether higher adherence and increased engagement are linked to increased efficacy.

Methods

We focused on a participant population of adults (aged ≥18 years) with depression or major depressive disorder as the primary diagnosis and included clinical trials, feasibility studies, and pilot studies of digital interventions for treating depression, such as digital therapeutics. We screened 756 unique records from Ovid MEDLINE, Embase, and Cochrane published between January 1, 2000, and April 15, 2022; extracted data from and appraised the 94 studies meeting the inclusion criteria; and performed a primarily descriptive analysis. Otsuka Pharmaceutical Development & Commercialization, Inc (Princeton, New Jersey, United States) funded this study.

Results

This SLR encompassed results from 20,111 participants in studies using 47 unique web-based interventions (an additional 10 web-based interventions were not described by name), 15 mobile app interventions, 5 app-based interventions that are also accessible via the web, and 1 CD-ROM. Adherence was most often measured as the percentage of participants who completed all available modules. Less than half (44.2%) of the participants completed all the modules; however, the average dose received was 60.7% of the available modules. Although engagement with digital interventions was measured differently in different studies, it was most commonly measured as the number of modules completed, the mean of which was 6.4 (means ranged from 1.0 to 19.7) modules. The mean amount of time participants engaged with the interventions was 3.9 (means ranged from 0.7 to 8.4) hours. Most studies of web-based (34/45, 76%) and app-based (8/9, 89%) interventions found that the intervention group had substantially greater improvement for at least 1 outcome than the control group (eg, care as usual, waitlist, or active control). Of the 14 studies that investigated the relationship between engagement and efficacy, 9 (64%) found that increased engagement with digital interventions was significantly associated with improved participant outcomes. The limitations of this SLR include publication bias, which may overstate engagement and efficacy, and low participant diversity, which reduces the generalizability.

Conclusions

Patient adherence to and engagement with digital interventions for depression have been reported in the literature using various metrics. Arriving at more standardized ways of reporting adherence and engagement would enable more effective comparisons across different digital interventions, studies, and populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderMobile ApplicationsAdultHumansAdolescentDepressionPatient Compliance

Stichwörter der Autor:innen

adherencedepressiondigital healthdigital interventionsdigital therapeuticsengagementmajor depressive disordermobile healthmobile phonesystematic literature review

Autor:innen und Institutionen

  • Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, United States.
  • Oxford PharmaGenesis Inc, Newtown, PA, United States.

ORCID-Profile: Ainslie Forbes, Madeline Rose Keleher, Michael Venditto, Faith DiBiasi

Zitieren

APA

Forbes, A., Keleher, M. R., Venditto, M., & DiBiasi, F. (2023). Assessing Patient Adherence to and Engagement With Digital Interventions for Depression in Clinical Trials: Systematic Literature Review. Journal of Medical Internet Research, 25, e43727. https://doi.org/10.2196/43727

Vancouver

Forbes A, Keleher MR, Venditto M, DiBiasi F. Assessing Patient Adherence to and Engagement With Digital Interventions for Depression in Clinical Trials: Systematic Literature Review. Journal of Medical Internet Research. 2023;25:e43727. doi:10.2196/43727

BibTeX
@article{Forbes2023,
  author = {Forbes, Ainslie and Keleher, Madeline Rose and Venditto, Michael and DiBiasi, Faith},
  title = {Assessing Patient Adherence to and Engagement With Digital Interventions for Depression in Clinical Trials: Systematic Literature Review},
  journal = {Journal of Medical Internet Research},
  year = {2023},
  volume = {25},
  pages = {e43727},
  doi = {10.2196/43727}
}
Kostenlos starten →